Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...
Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...
The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...
Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...
Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...
Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...
“These results strengthen our confidence in ecopipam as a potential first-in-class treatment for patients with Tourette syndrome,” said Frederick Munschauer, MD, Emalex Biosciences chief ...
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
Medpage Today on MSN2d
Banned Words at CDC? First Measles Death in Texas Outbreak; House Passes Budget BillCDC staff received an email this week telling them to avoid using more than a dozen terms or words -- including "health ...
Recent research has highlighted the significant role of Omega-3 fatty acids in supporting heart health, including some ...
Cision, a global leader in media intelligence and communications solutions, in partnership with PRWeek, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback